StockData
Medline Inc. logo

Medline Inc. (MDLN) company profile

MDLNNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 26, 2026Last filing: 10-Q on Nov 4, 2026Score 2/3065% above fair value
$39.17−0.30 (-0.76%)

Close on Nov 16, 2026Market cap $51.50BP/E –Yield –

About Medline

Surgical & Medical Instruments & Apparatus, SIC 3841

Medline Inc. manufactures and distributes medical-surgical supplies and provides healthcare supply chain management services. The company conducts business through two reportable segments: Medline Brand and Supply Chain Solutions. Through its Medline Brand segment, it provides proprietary items spanning patient front-line care, surgical and perioperative environments, and laboratory diagnostics, including wound care supplies, examination gloves, surgical procedure kits, and diagnostic instruments. Through its Supply Chain Solutions segment, Medline distributes third-party medical products alongside logistics optimization, third-party warehousing, consulting, and inventory management services. Its customers encompass all healthcare care settings, including hospitals, ambulatory surgery centers, physician clinics, and post-acute facilities.

The company employs over 45,000 workers worldwide, with more than 26,000 located in the United States and substantial teams in countries such as Mexico, the Dominican Republic, India, Canada, Slovakia, France, China, Japan, Germany, and Australia. Medline operates 30 manufacturing plants, 24 of which are in North America, and maintains 70 global distribution centers, warehouses, and transit hubs, with 45 across the United States supported by a private transport fleet exceeding 2,100 delivery trucks. The provided text does not mention the location of its headquarters.

Summary of the business section of Medline's latest annual report, written by StockData.

Company profile

Company

Legal name
Medline Inc.
Founded
1966
Headquarters
Northfield, IL
Address
3 Lakes Drive 60093
Phone
(847) 949-3000
Employees
45,000, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Chicago, Illinois

Stock & identifiers

Ticker
MDLN
Exchange
Nasdaq
IPO date
Dec 18, 2025
Shares outstanding
1.31B, Aug 3, 2026
Public float
$13.00B, Dec 17, 2025
Filer category
Non-accelerated filer
SEC CIK
2046386
CUSIP
58507V107
ISIN
US58507V1070
FIGI
BBG01Y6778L4
Share class FIGI
BBG01Y6779J5
LEI
984500FAN6J1P8566D43
EIN
33-1845288

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
James M. BoyleChief Executive Officer, Director3,084,818
Alexander M. LibermanChief Legal Officer1,270,811
Amanda H. LaabsChief Product Officer795,096
Douglas P. GolwasChief Commercial Officer1,323,309
Stephen L. MillerChief Operating Officer23,899
Christopher P. ShryockChief Human Resources Officer11,031
Michael B. DrazinChief Financial Officer509,927
William J. AbramsSee Remarks542,881
Jessi L. CorcoranPrincipal Accounting Officer5,000
James M. PigottPresident1,206,467
Thomas W. SweetDirector17,800
Todd M. BluedornDirector15,732
Richard A. GalantiDirector16,392
Patrick J. HealyDirector1,599,493
Robert R. SchmidtDirector–
Stephen H. WiseDirector–
Charles N. MillsDirector2,643,315
Andrew J. MillsDirector2,616,861
Anushka M. SunderDirector–
Jacob BestDirector–
Joseph BarattaDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$3.86M$61.84M$4.62M$102$101

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
James M. Boyle
Chief Executive Officer
$1.25M$1.18M$1.41M$23.35K$3.86M-10%
Michael B. Drazin
Chief Financial Officer
$810.00K$956.85K$763.12K$27.29K$2.56M-7%
James M. Pigott
President
$1.10M$0$930.57K$8.88M$10.91M+176%
Douglas P. Golwas
Chief Commercial Officer
$800.00K$956.85K$772.41K$25.03K$2.55M-7%
Stephen L. Miller
Chief Operating Officer
$800.00K$956.85K$676.78K$9.14K$2.44M-43%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Dec 18, 2025
Offer price
$29.00
Securities offered
216,034,482
Gross proceeds
$6.26B
Exchange
Nasdaq
First trading day
Dec 17, 2025
First-day close
$41.00+41.4%
Lock-up ends (est.)
Jun 15, 2026

“Per Share Total Initial public offering price $ 29.00 $ 6,264,999,978.00 Underwriting discounts and commissions (1) $ 0.63173 $ 136,475,463.31 Proceeds, before expenses, to Medline Inc.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?